On November 22, 2024, Clene announced the registration of up to 2,351,202 shares of common stock for resale by Selling Securityholders. This includes shares from private placements and warrants. Clene will not receive proceeds from these sales, except from warrant exercises. The company faces financial challenges, with a $7.8M loss in Q3 2024 and an accumulated deficit of $268.6M. Cash reserves dropped to $14.6M by September 30, 2024.Clene plans to raise additional funds through equity and debt financing, and cost-saving measures. The company is advancing clinical trials for ALS and MS treatments, with a Phase 3 ALS trial planned for 2025. Clene remains a smaller reporting company, benefiting from reduced reporting requirements.

On November 22, 2024, Clene announced the registration of up to 2,351,202 shares of common stock for resale by Selling Securityholders. This includes shares from private placements and warrants. Clene will not receive proceeds from these sales, except from warrant exercises. The company faces financial challenges, with a $7.8M loss in Q3 2024 and an accumulated deficit of $268.6M. Cash reserves dropped to $14.6M by September 30, 2024.Clene plans to raise additional funds through equity and debt financing, and cost-saving measures. The company is advancing clinical trials for ALS and MS treatments, with a Phase 3 ALS trial planned for 2025. Clene remains a smaller reporting company, benefiting from reduced reporting requirements.